36 results about "Immunization program" patented technology

The invention discloses a porcine transmissible gastroenteritis virus (PTGEV) and porcine epidemic diarrhea virus (PEDV) dual yolk antibody and a preparation method thereof. The preparation method comprises the following steps of: 1) preparing vaccines for immunization; 2) performing immunization; and 3) extracting the porcine PTGEV and PEDV dual yolk antibody, and purifying and freeze-drying theantibody. By adopting a special immunization program, the porcine PTGEV and PEDV dual yolk antibody has high potency. The porcine PTGEV and PEDV dual yolk antibody prepared by the method has the advantages of obvious effect, high specificity, quick treatment effect, accurate curative effect, low production cost and the like, and has good application prospect.

Conjugated meningococcal capsular saccharides will be introduced into immunization schedules in the near future, but the phenomenon of “carrier suppression” must first be addressed, particularly where multiple conjugates are to be used. It has been found that diphtheria toxoid and its derivatives (such as CRM197) can safely be used as the carrier protein, even where multiple meningococcal conjugates are administered at the same time and where a patient has previously been exposed to the carrier protein, either in the form of a previous immunogen (e.g. in a DTP vaccine) or as a previous carrier protein (e.g. in a Hib or pneumococcal conjugate vaccine). The invention provides a method for immunizing a patient, comprising administering multiple conjugates of meningococcal capsular saccharides, wherein each conjugate comprises a diphtheria toxoid (or derivative thereof) carrier protein, and the capsular saccharide, and wherein the patient has been pre-immunized with a diphtheria toxoid (or derivative thereof).

Conjugated meningococcal capsular saccharides will be introduced into immunization schedules in the near future, but the phenomenon of “carrier suppression” must first be addressed, particularly where multiple conjugates are to be used. In the invention, tetanus toxoid is used as the carrier protein, even where multiple meningococcal conjugates are administered at the same time and where a patient has previously been exposed to the carrier protein, either in the form of a previous immunogen (e.g. in a DTP vaccine) or as a previous carrier protein (e.g. in a Hib or pneumococcal conjugate vaccine). The invention provides a method for immunizing a patient, comprising administering multiple conjugates of meningococcal capsular saccharides, wherein each conjugate comprises a tetanus toxoid carrier protein, and the capsular saccharide, and wherein the patient has been pre-immunized with a tetanus toxoid.

The present invention relates to a treatment method for human peripheral blood T lymphocytes, preparation and application of immunogen preparations and antiserum, in which discarded white blood cell filter discs are used to separate and purify T lymphocytes, and the T lymphocytes are proliferated and cultured, and the isolated T lymphocytes Compared with the cultured T lymphocytes for antigen surface marker identification and activity comparison; then the expanded and cultured highly active T lymphocytes were used as immunogens, and healthy pigs were used to prepare antiserum, and E rosette inhibition experiments and cell Toxicity test results to evaluate the potency after immunization, formulate immunization procedures, and then a large amount of antiserum can be prepared; then anti-plasma is collected for plasma separation and used for the preparation of ALG products. The present invention can solve the restriction problem that fresh whole blood needs to be collected each time in the potency test of raw materials for preparation of anti-human T lymphocyte immunoglobulin and the potency test of finished products, and can also solve the problem of the bottleneck of the raw material of anti-human T lymphocyte immunoglobulin .

The invention relates to a vaccine composition, which contains classical swine fever virus antigen, porcine circovirus type 2 antigen, mycoplasma hyopneumoniae antigen and a vaccine adjuvant. The invention also provides a method for preparing the vaccine composition, a water-soluble vaccine adjuvant is used for preparing a mixture of the porcine circovirus type 2 antigen and mycoplasma hyopneumoniae antigen, and the mixture is taken as a diluent for diluting classical swine fever virus antigen. The vaccine composition has the advantages of simple preparation method, high titer content of the vaccine, and convenient and fast immunization, one time immunization can simultaneously preventing or treating swine fever, porcine circovirus type 2 antigen and mycoplasma hyopneumoniae, immunization cost is reduced, the immunization program is saved, and the application is more economic and reliable.

The invention relates to a method for identifying chicken infectious bronchitis virus (IBV). The method is to inoculate SPF chicken embryos into the allantoic cavity of the sample to be tested, and set the SPF chicken embryos inoculated with PBS buffer solution as a control at the same time. Chicken embryos were incubated at 37°C for 24-30 hours, and then inoculated with attenuated Newcastle disease virus strain at 200-2000 times the half infectious dose (EID50) of chicken embryos, and then incubated at 37°C for 48-72 hours to detect the hemagglutination value of chicken embryo allantoic fluid , according to the hemagglutination value judgment result. This method utilizes the characteristic that IBV virus can interfere with the proliferation of chicken Newcastle disease virus (NDV) in chicken embryos, and can be used for laboratory diagnosis, antibody detection and IBV serotype identification of chicken infectious bronchitis, so as to carry out chicken infectious bronchitis vaccine immunization The evaluation of the effect and the monitoring of the epidemic situation provide a theoretical basis for formulating a scientific immunization program and effectively preventing and controlling the occurrence of the disease.

The invention relates to a rabbit pestivirus antibody rapid detection card and a preparation method thereof. The preparation method comprises the following concrete steps: (1) preparing an anti-rabbit-pestivirus VP60 monoclonal antibody, concretely performing immunization program, cell fusion, hybridomas screening and cloning, and antibody preparation and purification; and (2) preparing the rabbit pestivirus antibody rapid detection card, concretely decocting a colloidal gold solution, marking the anti-rabbit-pestivirus VP60 monoclonal antibody, processing a colloidal-gold pad, processing a sample pad, and determining C and T lines. The rabbit pestivirus antibody rapid detection card is capable of rapidly, sensitively and accurately detecting rabbit pestivirus antibody, and overcomes the problems that domestic rabbit pestivirus antibody detection mainly employs erythrocyte hemagglutination and ELISA detection.

The invention provides a vaccine composition containing a swine mycoplasmal pneumonia antigen and a swine streptococcosis antigen, and a preparation method and an application thereof. The vaccine composition includes an immunizing dose of the swine mycoplasmal pneumonia antigen, an immunizing dose of the swine streptococcosis antigen, and an adjuvant. The vaccine composition has a simple immunization program, can effectively control the swine mycoplasmal pneumonia antigen and the swine streptococcosis antigen, has an immune effect equivalent to the immune effect realized through respective injection of single vaccines, and also has the characteristics of small side reaction, long immune period, less time consumption, and less labor consumption; and the vaccine composition also has the advantages of simple production technology, low immune cost and strong practicality.

Disclosed are the methods of curing HBV infection and providing complete protection against HBV infection in a simplified HBV immunization schedule. The mechanistic basis for curing HBV infection is founded on the understanding that hepatitis B virus infection is established and prolonged by new rounds of infection with continuously produced viruses, which are not fully neutralized because of insufficient endogenous neutralizing antibodies. The methods of curing HBV infection including chronic HBV infection are aimed to block new rounds of HBV infection. The guidelines for establishing treatment regimens for curing HBV infection, include production or administration of sufficient level of HBV neutralizing antibodies in treated patients. Among the many different possibilities contemplated, the sufficient level of HBV neutralizing antibodies is expressed and maintained by the single injection of the HBV therapeutics that comprises non-replicating viruses or vectors encoding HBV neutralizing antibodies or by multi-injection of exogenous HBV neutralizing antibodies.

The present invention relates to the composition and method of preparing an immunogen designated as I-spga consisting of a complex antigen prepared from 18 to 26 species of pathogenic microorganisms isolated from patients, inactivated with binary ethyleneamine (BEI) and formalin, diluted in a SPGA immunopotentiator mixed with QS-21 adjuvant. By inoculating the hens with the I-spga immunogen, hyperimmune eggs (Immunospga) are obtained which contain immunologically active proteins specific to the 18-26 antigens used for immunization. The immune response of the hens is specific to the used antigens by amplification of the antigenic signal by the SPGA immunopotentiator and due to a special immunization program that allows the immune system to act complex and intense: The I-spga complex antigen contains 18-26 microorganisms isolated from patients, bacterial bodies, components from bodies obtained by ultrasonography, cilia, exotoxins, endotoxins, spores, viruses, fungi or yeasts. This pathogenic material is inactivated with BEI and formalin. The I-spga antigen is of three types. The standard I-spga antigen is composed of 18 to 24 antibiotic-resistant bacterial species isolated from patients in Romania. The specific I-spga complex antigen is composed of the I-spga complex antigen containing a mixture of 7-9 strains from a single species of bacteria, fungi or yeasts isolated from patients in Romania mixed with SPGA and QS-21, used for inoculation of hens previously immunized with standard I-spga antigen. The personalized I-spga antigen is composed of patient-derived pathological material containing cellular debris and pathogenic germs inactivated with BEI and formalin and mixed with SPGA and QS-21 and is used to immunize hens previously immunized with the standard I-spga antigen. This now patented technology encompasses a new generation of biological products in which the immune response of the hens to different groups of parenterally inoculated antigens at different time intervals is overlapping. Chicken response is uniform and additional administration of immunogens and SPGA as an immunopotentiator amplifies the antigenic signal and immune response. The I-spga immunogen as well as the immune response contain two markers, G and A, which identify the I-spga antigen used for immunization against the antigens used to produce the Imunoinstant group bio-preparations or similar products. The I-spga immunogen is used to immunize the hens for obtaining immunologically active proteins that can be used to treat immune deficiencies, psoriasis, epidermolysis bullosa, other dermatitises, nosocomial infections, antibiotic-resistant infections in the urinary system of children and grownups.